Glenn Holmwood

Before Hausfeld, Glenn was part of the legal team at the Competition and Markets Authority that:

• Successfully defended appeals before the Competition Appeal Tribunal from pharmaceutical suppliers against a finding that they had charged excessive and unfair prices over a decade for hydrocortisone tablets, a generic medicine used in the treatment of Addison’s disease and funded by the NHS. This resulted in the upholding of almost £130 million in fines, the highest ever CMA penalties upheld by the Tribunal.
• Acted on two CMA firsts: the first antitrust director disqualification and the first litigation-led enforcement of an Initial Enforcement Order (IEO) imposed in a merger investigation which resulted in a £50m fine.
• Ran a complex appeal on the starting point for the assessment of costs in the regulatory regime from the Competition Appeal Tribunal to the Court of Appeal and eventually to the Supreme Court.

At Hausfeld, he is part of the legal team working on:

• Filing a representative collective action with the CAT on behalf of the Consumers’ Association (known as Which?) against Qualcomm on behalf of a class of around 29 million UK consumers alleging that Qualcomm abuses its dominance in the markets for smartphone chipsets and standard essential patents, the result of which is that Qualcomm is able to overcharge smartphone manufacturers like Apple and Samsung for its technology. Damages are estimated to be over £480 million.